News

Nomic Bio Awards 7 Research Teams in Their First Grant Program

Congratulations to our portfolio company, Nomic Bio, on awarding their first Omni 1000 Grant program.

Seven research teams will now gain access to 5,000 samples and 5 million protein datapoints – a scale of proteomic analysis rarely achievable in today’s constrained funding environment.

Why does this matter? These projects span some of the most pressing areas in medicine, including:

  • Predicting which cancer patients will respond to immunotherapy
  • Uncovering shared risk drivers in lung diseases and cancer
  • Advancing drug discovery for inflammatory bowel disease
  • Developing biomarkers to safely expand access to liver transplantation

By democratizing access to proteomics at scale, Nomic is enabling discoveries that can directly impact patient care and accelerate therapeutic innovation.

We’re proud to back Nomic as they equip scientists with the tools to answer today’s most ambitious questions in biology.

Press Release